Third, there is presently no clear evidence that use of SGLT2is in patients with cancer leads to improvement in anticancer outcomes, although clinical trials are now beginning to use SGLT2is in conjunction with other established antineoplastic agents.9,10 Finally, if monoclonal antibodies against immune checkpoints, such as PD-L1, already exist, what would be the advantage of SGLT2 inhibition? This evidence concerns the gene CD274 and cancer.